Anila Panezai, Sara Inayat, Saif Ullah, Habib Ullah, Mehvish Afridi, Sehrish Ghani.
ECG manifestations of meglumine antimoniate in treatment of cutaneous leishmaniasis.
J Pak Assoc Derma Jan ;30(3):382-7.

Objective To determine ECG manifestations of Meglumine Antimoniate in treatment of cutaneous leishmaniasis for cutaneous leishmaniasis. Study Design: Cross Sectional.   Setting & Study duration   This study was conducted at the Department of Dermatology, Bolan Medical College/ Sandeman Provincial Hospital, Quetta from 20th August 2015 to 20th February 2016 (6 months).   Material and Methods A total of 245 patients were included in the study. All patients between the ages of 25 to 60 years diagnosed as leishmaniasis and on treatment for > 2 weeks were enrolled. The patients were treated with intra-muscular injections of MA (Glucantime; Aventis, France) at a dose of 20 mg/day for 21 days.  ECG was captured on a standard 12 leads format. The diagnosis of ECG manifestations was made based on recording of ECG done at 1 st and fourth week after starting treatment. Data was analyzed using Statistical package of Social Sciences (SPSS) version 19. Mean + SD were calculated for continuous variable of age, height, weight, BMI, daily dose and duration of treatment. Results on categorical variables of gender and patient outcome variable i-e Sinus tachycardia, sinus bradycardia, prolong QT interval, T inversion, ST Depression, Q wave were expressed in frequencies and proportions. Stratification of age, gender, duration of treatment, duration of disease and daily dose was done to see their effect on outcome variable.   Results A total of 245 patients were included in the study. Mean age of the patients was 54.34±5.02 years. Majority of the patients 189 (77.1%) were males. Mean duration of treatment and duration of disease was 4.98 ±1.56 weeks and 6.20 ±1.82 weeks respectively. Frequency of sinus tachycardia was found in 37 (15.1%) patients, sinus bradycardia 19 (7.8%), T wave inversion 12 (4.9%), prolong QT inversion 38 (15.5%), ST depression 13 (5.3%) while Q wave was observed in 67 (27.3%) patients.9.23 years.   Conclusion Our results showed that treatment with Meglumine antimoniate can induce many ECG changes. We suggest that ECG monitoring should be performed in high-risk patients undergoing Meglumine antimoniate treatment with special attention to ECG changes.  

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com